# Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

> **NCT00234000** · PHASE1 · TERMINATED · sponsor: **Jonsson Comprehensive Cancer Center** · enrollment: 1 (actual)

## Conditions studied

- Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** arsenic trioxide
- **DRUG:** azacitidine

## Key facts

- **NCT ID:** NCT00234000
- **Lead sponsor:** Jonsson Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-02
- **Primary completion:** 2009-02
- **Final completion:** —
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** The study was closed due to poor enrollment
- **Last updated:** 2020-07-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00234000

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00234000, "Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT00234000. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*